Related Experiment Video
Updated: Aug 10, 2025
05:41
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
3.0K
Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy
Ajit Sood1, Arshdeep Singh1, Vandana Midha2
1Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India.
Crohn'S & Colitis 360
|February 13, 2023
Summary
Fecal microbiota transplantation (FMT) shows promise for ulcerative colitis but requires further research. Key considerations include donor/recipient selection, administration, and assessing treatment response for this evolving therapy.
Area of Science:
- Gastroenterology
- Microbiome research
- Immunology
Background:
- Fecal microbiota transplantation (FMT) is approved for recurrent C. difficile infection.
- Its application in ulcerative colitis (UC) is nascent, with limited understanding of mechanisms and practicalities.
Purpose of the Study:
- To address unresolved issues regarding FMT for UC.
- To explore donor/recipient selection, administration routes, therapy duration, response assessment, and regulatory status.
Main Methods:
- Literature review and expert discussion on current FMT practices for UC.
- Analysis of factors influencing FMT efficacy, including diet and microbiome interactions.
Main Results:
- Identified critical gaps in knowledge for FMT in UC.
- Proposed a nomenclature change to "fecal microbiome transfer" (FMT).
Conclusions:
- Fecal microbiota transplantation (FMT) is an evolving treatment for UC.
- Further clinical trials are essential to guide its use and role in managing ulcerative colitis.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
211
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
211
01:21Inflammatory Bowel Disease V: Surgical Management
185
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
185
01:17Drugs for Treatment of Diarrhea-Predominant IBS
254
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
254
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
227
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
227
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
267
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
267
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
384
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
384